Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Melphalan × Other solid neoplasm × Clear all

Phase

Phase 1 6 Phase NA 3 Phase 3 1 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4 Myeloid 3 Lymphoid 3 Plasma cell 2 Classical hematology 2 Sarcoma 1 Other solid neoplasm 1 Genitourinary 1 Dermatologic 1 CNS 1

Conditions

Retinoblastoma 1

Interventions

pembrolizumab 3 Pemetrexed 3 Cisplatin 3 Drug Therapy 2 Carboplatin 2 toripalimab 1 tislelizumab 1 spartalizumab 1 sintilimab 1 penpulimab 1 nintedanib 1 camrelizumab 1 balstilimab 1 atezolizumab 1 anlotinib 1 Vincristine 1 Topotecan 1 Sentinel Lymph Node Biopsy 1 Platinum Compounds 1 Melphalan 1 Inosine 1 Injections 1 Indocyanine Green 1 Immunotherapy 1 Hyperthermia, Induced 1 Etoposide 1 Cryotherapy 1 ADI PEG20 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04681417 2025-11-28

RETINO 2018

Institut Curie

Phase 2/3 Recruiting

Other solid neoplasm

Retinoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡